Galderma has pledged to invest more than $650m on US manufacturing, as the drugmaker looks to meet increasing demand for its dermatology products, including its current growth driver Nemluvio (nemolizumab).
The funding outlay, which will be spent up to 2030, includes ramping up final assembly and packaging for Nemluvio in Florida via Galderma’s contract manufacturing partner.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nemluvio obtained several regulatory approvals within the past year. The drug gained US Food and Drug Administration (FDA) approval for the treatment of moderate-to-severe atopic dermatitis, also called eczema, in December 2024, adding to its indication in prurigo nodularis from August 2024. In February 2025, Nemluvio gained approval in Europe for the same two skin conditions.
Nemluvio’s net sales for the first nine months reached $263m. Galderma said revenue predominantly came from the US and prurigo nodularis, although atopic dermatitis started contributing to a greater share of sales in Q3.
The bolstering in US manufacturing capabilities is timely, with sales for the drug anticipated to surge in coming years. Analysis by GlobalData’s Pharma Intelligence Centre forecasts Nemluvio will enter blockbuster territory by 2027. The same analysis forecasts global revenue to reach $3.2bn in 2031.
GlobalData is the parent company of Pharmaceutical Technology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We continue to meet evolving consumer and patient needs, with Nemluvio showing outstanding momentum and driving significant growth. To support this, we are deepening our investments in the US, expanding our presence, and strengthening partnerships with healthcare professionals,” said Galderma’s CEO, Flemming Ørnskov.
Nemluvio helped spur a positive first nine months of the year for Galderma, with record revenue of $3.7bn posted in its Q3 results. This led to annual growth guidance being upped to 17% to 17.7%, compared to a previous target of 12% to 14%.
As part of the US footprint double down, Galderma and its manufacturing partners have initiated additional technology transfers to the US. The Swiss company said these would focus on “key growth drivers”, which includes securing double-sourcing of Relfydess’ US capacity. Relfydess is a prescription-only botulinum toxin for wrinkle treatment.
Alastin and certain Cetaphil products, two of Galderma’s consumer health brands, also stand to benefit from Galderma’s US funding outlay.
The $650m investment sees Galderma continue building its US presence. In June 2025, the dermatology specialist established new US headquarters in Miami. Galderma’s US therapeutic dermatology business and research and development organisation hub resides in Boston.
Galderma becomes the latest European pharma company to heavily invest in the US this year amid pressures from President Donald Trump. Roche has pledged $50bn to expand its footprint in the country, while AstraZeneca has outlaid $50bn for the same purpose.
One of Trump’s administration’s main aims is to incentivise drug companies to move manufacturing operations to the US and decrease reliance on pharmaceutical imports from other countries.
